ArticleOrphanet journal of rare diseases2025
Pulmonary vascular Ehlers-Danlos syndrome with hemoptysis as the main manifestation: CT and histologic findings of lung parenchymal damage.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pulmonary hemorrhage as an early clue: an integrated clinical-imaging-genetic diagnostic insight for vascular Ehlers-Danlos syndrome.Orphanet journal of rare diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundVascular Ehlers-Danlos syndrome (vEDS) is a rare inherited connective tissue disease caused by mutations in the COL3A1 gene. The disease can cause fatal complications such as rupture of the arteries, uterus, and intestine, as well as pulmonary complications, including spontaneous pneumothorax and hemoptysis. Since hemoptysis in vEDS is rare and often misdiagnosed, this study aims to summarize its clinical features, CT findings and the diagnosis and treatment process, thereby improving clinical understanding.
methodsPatients with vEDS presenting with hemoptysis treated at the First Affiliated Hospital of Guangzhou Medical University from May 2017 to December 2024 were collected. Inclusion criteria included hemoptysis, chest CT, and COL3A1 gene test results. The clinical manifestations, CT and pathological data of the patients were collected.
resultsThe cohort included eight males and one female (mean age 22.22 ± 5.72 years). All patients presented with recurrent hemoptysis and cough. The CT findings included patchy ground-glass opacities, fibrous cords, nodules, and cavities, which were predominantly located in the lower lungs. 5 cases showed diffuse erythrocyte exudation and increased hemosiderin-laden macrophages. Eight cases were initially misdiagnosed as infectious diseases, of which 4 cases were treated with diagnostic anti-tuberculosis therapy.
conclusionThis study demonstrates that the clinical and imaging manifestations in vEDS patients presenting with hemoptysis lack specificity and are frequently misdiagnosed as infectious diseases. For young men with repeated hemoptysis and persistent CT abnormalities, especially when anti-infective treatment proves ineffective, vEDS should be considered and early genetic testing should be performed. Early diagnosis is crucial to prevent severe complications. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.